Supporting Information

DHDMIQK(KAP): A novel nano-delivery system of dihydroxyl-tetrahydro-isoquinoline-3-carboxylic acid and KPAK towards the thrombus

Qiqi Feng,a Ming Zhao*ab Taiping Gan,a Haimei Zhu,a Yaonan Wang,a Shurui Zhao,a Yuji Wang,a Jianhui Wua and Shiqi Peng*ab

aBeijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, P. R. China
E-mail: mingzhao@bjmu.edu.cn, sqpeng@bjmu.edu.cn; Fax: +86-10-8280-2482, +86-10-8391-1528; Tel: +86-10-8280-2482, +86-10-8391-1528
b Faculty of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan

*To whom correspondence should be addressed. SP: College of Pharmaceutical Sciences, Capital University of Medical Sciences, Beijing 100069, P.R. China. Tel: 86-10-8391-1528, Fax: 86-10-8391-1528, E-mail: shiqipeng@163.com or sqpeng@bjmu.edu.cn; MZ: Tel.: +86-10-8280-2482, fax: +86-10-8280-2482, E-mail: mingzhao@bjmu.edu.cn

‡ These authors contributed equally.
Experimental section

1. $^1$HNMR spectrum of DHDMIQK(KAP)

![HNMR spectrum of DHDMIQK(KAP)](image)

Fig. S1 $^1$HNMR spectrum of DHDMIQK(KAP).

2. $^{13}$CNMR spectrum of DHDMIQK(KAP)
3. COSY 2D NMR spectrum of DHDMIQK(KAP)

4. NOESY 2D $^1$H NMR of DHDMIQK(KAP)
5. HPLC purity of DHDMIQK(KAP)

A Waters 2695 HPLC system with a Waters 2996 PDA was used. The sample was analyzed on a Waters X-Terra C₁₈ reversed-phase column (column 4.6×150 mm, 3.5 μm; Waters Limited, Hertfordshire, UK). Onto the column, 5 μL of a solution of DHDMIQK(KAP) in acetonitrile was injected. The mobile phase was acetonitrile containing trifluoroacetic acid (0.1%). The flow rate was 1 mL/minute. The UV detector was set to a scanning range of 200-400 nm, and a wavelength of 254 nm was used to monitor DHDMIQK(KAP), of which the retention time was 5.366 minutes and the purity was 98.93%. 
Fig. S5 HPLC purity of DHDMIQK(KAP).

6. ESI(+) / FT-MS spectrum of DHDMIQK(KAP)

The FT-MS spectrum of DHDMIQK(KAP) in water are shown in Fig. S6A which gives a positive ion peak of \([1/2M + H]^+\) at 1986.17767, the mass of a hexamer plus H, a positive ion peak of \([1/2M + H]^+\) at 1654.47219, the mass of a pentamer plus H, a positive ion peak of \([M + H]^+\) at 1985.18013, the mass of a trimer plus H, a positive ion peak of \([M + H]^+\) at 1323.78001, the mass of a dimer plus H, a positive ion peak of \([M + H]^+\) at 662.38787, the mass of a monomer plus H. Fig. 6B is a qCID spectrum, the pentamer is the fragmentation product of the hexamer. Fig. 6C is a qCID spectrum, the dimer is the fragmentation product of the pentamer. Fig. 6D is a qCID spectrum, the monomer is the fragmentation product of the dimer.
Fig. S6 ESI(+)FT-MS full scan spectrum (A) and qCID ion scan spectrum (B-D).

7. Biodistribution of DHDMIQK(KAP)
Fig. S7 FT-MS spectra of the extracts of the thrombus and blood of DHDMIQK(KAP) treated rats. (A) FT-MS spectrum of the extract of the thrombus and the amplified ion peak of DHDMIQK(KAP) and ion peak of KPAK; (B) FT-MS spectrum of the extract of the thrombus and the amplified anion peak of 6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.